Johnson & Johnson (NYSE:JNJ) Position Increased by Howland Capital Management LLC

Posted by Defense World Staff on Apr 19th, 2023

Howland Capital Management LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 152,880 shares of the company’s stock after acquiring an additional 1,616 shares during the period. Johnson & Johnson accounts for 1.7% of Howland Capital Management LLC’s portfolio, making the stock its 14th biggest holding. Howland Capital Management LLC’s holdings in Johnson & Johnson were worth $27,006,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of JNJ. Nordwand Advisors LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $785,273,000. Vanguard Group Inc. lifted its holdings in Johnson & Johnson by 1.2% in the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after purchasing an additional 2,815,655 shares during the period. GQG Partners LLC lifted its holdings in Johnson & Johnson by 64.4% in the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after purchasing an additional 2,547,378 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in Johnson & Johnson by 37.2% in the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after purchasing an additional 1,805,632 shares during the period. Finally, First Trust Advisors LP lifted its holdings in Johnson & Johnson by 62.6% in the first quarter. First Trust Advisors LP now owns 2,785,312 shares of the company’s stock worth $493,640,000 after purchasing an additional 1,072,104 shares during the period. Institutional investors own 67.94% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on JNJ shares. StockNews.com started coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Atlantic Securities upped their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a report on Wednesday, January 25th. SVB Leerink reduced their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Guggenheim started coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 1st. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $173.07.

Insider Activity

In other news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.20% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ stock opened at $161.01 on Wednesday. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. Johnson & Johnson has a one year low of $150.11 and a one year high of $186.69. The firm has a market capitalization of $419.32 billion, a PE ratio of 23.89, a P/E/G ratio of 2.86 and a beta of 0.53. The firm has a 50-day moving average of $157.50 and a two-hundred day moving average of $167.03.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. During the same period in the prior year, the firm earned $2.67 earnings per share. The business’s quarterly revenue was up 5.6% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current year.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.